Serial No.: 10/079,452 20832Y Case No.:

Page No.:

AMENDMENT

Please amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:


Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

è

Claim 1(previously presented): A compound having the formula (I):



or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring;

HetAr is a 5 or 6 membered heteroaromatic ring containing 1-3 nitrogen ring atoms, or isoxazolyl, thiazolyl, thiadiazolyl, quinolinyl, quinazolinyl, purinyl, pteridinyl, benzimidazolyl, pyrrolopyrimidinyl, or imidazopyridinyl;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C1-4alkyl, C1-4alkoxy, C2-4alkynyl, trifluoromethyl, hydroxy, hydroxyC1-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl) 2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-;

A is -C₁₋₄alkyl-;

10/079,452

Page No.:

20832Y

B is $aryl(CH_2)_{0.3}$ –O–C(O)–, heteroaryl(CH₂)_{1.3}–O–C(O)–, indanyl(CH₂)_{0.3}–O–C(O)–, aryl(CH₂)_{1.3}–C(O)–, aryl–cyclopropyl–C(O)–, heteroaryl–cyclopropyl–C(O)–, heteroaryl(CH₂)_{1.3}–C(O)–, aryl(CH₂)_{1.3}–NH–C(O)–, aryl(CH₂)_{1.3}–NH–C(NCN)–, aryl(CH₂)_{1.3}–SO₂–, heteroaryl(CH₂)_{1.3}–SO₂–, wherein any of the aryl or heteroaryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro; and

3

X is H, OH, F, C₁₋₄alkyl, C₁₋₄alkoxy, NH₂, or X taken with an adjacent bond is =0.

Claim 2(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is aryl(CH₂)_{0.3}–O–C(O)–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 3(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkynyl, trifluoromethyl, hydroxy, hydroxy C_{1-4} alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,— $N(C_{0-4}$ alkyl)(C_{0-4} alkyl), nitro, (C_{1-2} alkyl)(C_{1-2} alkyl)NCH₂—, (C_{1-2} alkyl)HNCH₂—, Si(CH₃)3—C—, or NH₂C(O)—.

Claim 4(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is an isoxazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂–, (C₁₋₂alkyl)HNCH₂–, Si(CH₃)₃–C–, or NH₂C(O)–.

Serial No.: 10/079,452 Case No.: 20832Y

Page No.: 4

Claim 5(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

ì

HetAr is a thiadiazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkynyl, trifluoromethyl, hydroxy, hydroxy C_{1-4} alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—, $-N(C_{0-4}$ alkyl)(C_{0-4} alkyl), nitro, (C_{1-2} alkyl)(C_{1-2} alkyl)NCH2—, (C_{1-2} alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

Claim 6(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 5 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C_1 -4alkyl, C_1 -4alkoxy, C_2 -4alkynyl, trifluoromethyl, hydroxy, hydroxy C_1 -4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,-N(C_0 -4alkyl)(C_0 -4alkyl), nitro, (C_1 -2alkyl)(C_1 -2alkyl)NCH2—, (C_1 -2alkyl)HNCH2—, Si(C_1 -3alkyl)-C—, or NH2C(C_1 -2alkyl)-C—.

Claim 7(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is quinolinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 8(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–,

Serial No.: 10/079,452 Case No.: 20832Y

Page No.: 5

heteroarylethynyl-,- $N(C_0$ -4alkyl)(C_0 -4alkyl), nitro, (C_1 -2alkyl)(C_1 -2alkyl)NCH₂-, (C_1 -2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 9(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C_1 -4alkyl, C_1 -4alkoxy, C_2 -4alkynyl, trifluoromethyl, hydroxy, hydroxy C_1 -4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,-N(C_0 -4alkyl)(C_0 -4alkyl), nitro, (C_1 -2alkyl)(C_1 -2alkyl)NCH2—, (C_1 -2alkyl)HNCH2—, Si(C_1 -3alkyl)-C—, or NH2C(O_1 -2alkyl)-C.

Claim 10(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is thiazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkynyl, trifluoromethyl, hydroxy, hydroxy C_{1-4} alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—, $-N(C_{0-4}$ alkyl)(C_{0-4} alkyl), nitro, (C_{1-2} alkyl)(C_{1-2} alkyl)NCH2—, (C_{1-2} alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

Claim 11(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pteridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkynyl, trifluoromethyl, hydroxy, hydroxy C_{1-4} alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—, $-N(C_{0-4}$ alkyl)(C_{0-4} alkyl), nitro, $(C_{1-2}$ alkyl)(C_{1-2} alkyl)NCH₂—, $(C_{1-2}$ alkyl)HNCH₂—, $(C_{1-2}$ Al

Claim 12(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyrrolopyrimidinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy,

10/079,452 20832Y

Page No.:

6

hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,- $N(C_{0-4}alkyl)(C_{0-4}alkyl)$, nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 13(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a imidazopyridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,—N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂—, (C₁₋₂alkyl)HNCH₂—, Si(CH₃)₃—C—, or NH₂C(O)—.

Claim 14(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is benzimidazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkynyl, trifluoromethyl, hydroxy, hydroxy C_{1-4} alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,— $N(C_{0-4}$ alkyl)(C_{0-4} alkyl), nitro, (C_{1-2} alkyl)(C_{1-2} alkyl)NCH₂—, (C_{1-2} alkyl)HNCH₂—, Si(CH₃)3—C—, or NH₂C(O)—.

Claim 15(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is aryl(CH₂)₁₋₃–SO₂–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 16(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms; HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-

10/079,452

Case No.: Page No.: 20832Y

4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 17(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is quinazolinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkynyl, trifluoromethyl, hydroxy, hydroxy C_{1-4} alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,- $N(C_{0-4}$ alkyl)(C_{0-4} alkyl), nitro, (C_{1-2} alkyl)(C_{1-2} alkyl)NCH₂-, (C_{1-2} alkyl)HNCH₂-, Si(C_{1-2} alkyl)3- C_{1-2} -, or NH₂C(O_{1-2} -.

Claim 18(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_1 -4alkyl, C_1 -4alkoxy, C_2 -4alkynyl, trifluoromethyl, hydroxy, hydroxy C_1 -4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C_0 -4alkyl)(C_0 -4alkyl), nitro, (C_1 -2alkyl)(C_1 -2alkyl)NCH2-, (C_1 -2alkyl)HNCH2-, Si(C_1 -3alkyl)-C-, or NH2C(C_1 -2alkyl)-C-.

Claim 19(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is imidazopyridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 20(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom; and

10/079,452

Page No.:

20832Y

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C_1 -4alkyl, C_1 -4alkoxy, C_2 -4alkynyl, trifluoromethyl, hydroxy, hydroxy C_1 -4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,- $N(C_0$ -4alkyl)(C_0 -4alkyl), nitro, (C_1 -2alkyl)(C_1 -2alkyl)NCH2—, (C_1 -2alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

Claim 21(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 5 membered ring containing 1 nitrogen ring atom; and B is aryl(CH₂)₀₋₃–O–C(O)–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 22(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms; HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 23(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is pteridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_1 -4alkyl, C_1 -4alkoxy, C_2 -4alkynyl, trifluoromethyl, hydroxy, hydroxy C_1 -4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—, $-N(C_0$ -4alkyl)(C_0 -4alkyl), nitro, $(C_1$ -2alkyl)(C_1 -2alkyl)NCH2—, $(C_1$ -2alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

Claim 24(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

10/079,452

Case No.: Page No.: 20832Y

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_1 -4alkyl, C_1 -4alkoxy, C_2 -4alkynyl, trifluoromethyl, hydroxy, hydroxy C_1 -4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,-N(C_0 -4alkyl)(C_0 -4alkyl), nitro, (C_1 -2alkyl)(C_1 -2alkyl)NCH2—, (C_1 -2alkyl)HNCH2—, Si(C_1 -3alkyl)-C—, or NH2C(C_1 -2alkyl)-C—.

Claim 25(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is benzimidazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 26(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is an aza bicyclo octane ring; and

B is $aryl(CH_2)_{0-3}$ –O–C(O)–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 27(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom; and HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 28(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

10/079,452 20832Y

Page No.:

10

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkynyl, trifluoromethyl, hydroxy, hydroxy C_{1-4} alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,- $N(C_{0-4}$ alkyl)(C_{0-4} alkyl), nitro, (C_{1-2} alkyl)(C_{1-2} alkyl)NCH₂-, (C_{1-2} alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 29(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atom; and HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)–.

Claim 30(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is an aza bicyclo octane ring; and

B is $aryl(CH_2)_{1.3}$ –SO₂–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 31(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is heteroaryl(CH₂)₁₋₃-C(O)-, wherein the heteroaryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 32(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and

Page No.:

10/079,452 20832Y

B is $aryl(CH_2)_{1-3}$ –C(O)–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

•

Claim 33(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and

B is aryl-cyclopropyl-C(O)-, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{1-4} alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 34(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyridyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkynyl, trifluoromethyl, hydroxy, hydroxy C_{1-4} alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,— $N(C_{0-4}$ alkyl)(C_{0-4} alkyl), nitro, (C_{1-2} alkyl)(C_{1-2} alkyl)NCH₂—, (C_{1-2} alkyl)HNCH₂—, Si(CH₃)3—C—, or NH₂C(O)—.

Claim 35(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyrazinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_1 -4alkyl, C_1 -4alkoxy, C_2 -4alkynyl, trifluoromethyl, hydroxy, hydroxy C_1 -4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,— $N(C_0$ -4alkyl)(C_0 -4alkyl), nitro, (C_1 -2alkyl)(C_1 -2alkyl)NCH2—, (C_1 -2alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

Claim 36(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyridazinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–,

10/079,452

Case No.: Page No.:

20832Y

phenylethynyl-, heteroarylethynyl-,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 37(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyrimidinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 38(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is heteroaryl(CH₂)₁₋₃-O-C(O)-, wherein the heteroaryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro;.

Claim 39(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is aryl(CH₂)₁₋₃-NH-C(NCN)-, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 40(original): The compound according to Claim 1, wherein said compound is

10/079,452 20832Y

Page No.:

13

	O N H N N N N N N N N N N N N N N N N N	
NH NH N		O N H N O
		$\left\langle \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \\ \\ \end{array} \right\rangle = 0$

10/079,452 20832Y 14

Case No.: Page No.:

S N N N N N N N N N N N N N N N N N N N		HN P P O O
		O N N N N N N N N N N N N N N N N N N N
F O N H	CI N N N N N N N N N N N N N N N N N N N	

10/079,452 20832Y 15

Page No.:

F N N N N N N N N N N N N N N N N N N N	CI N N N N N N N N N N N N N N N N N N N	O O O O O O O O O O O O O O O O O O O
N OH	CH ₃	H H N N N N N N N N N N N N N N N N N N
HN NC	O N HN N CI	ON NO N
O N HN N	O O O O O O O O O O O O O O O O O O O	

10/079,452 20832Y 16

Page No.:

HO_NH N-O	N-NH-NH-N-S	HN NH NH
	OH H N	Br NH N-O
F NH O		
CI NH NH O		
		ZH ZH ZH O

ï

10/079,452 20832Y 17

Case No.: Page No.:

		CI NH NH NH O
	O N H N N N N N N N N N N N N N N N N N	
F N N O O	CI N H N N F	F N N N N F
	N—NH—N—O	N HN O
N N N O N O N O N O N O N O N O N O N O	HN N N O	HN_N N-O

10/079,452 20832Y 18

Case No.: Page No.:

or a pharmaceutically acceptable salt thereof.

The compound according to Claim 1, wherein said compound is Claim 41(original):

	N HN O N S S S S S S S S S S S S S S S S S	
N N N N N N N N N N N N N N N N N N N	H ₂ N—NH—N=S	NH O O O O O O O O O O O O O O O O O O O
N N N O S S S S S S S S S S S S S S S S		N—NH 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	NH O O O O O O O O O O O O O O O O O O O	N NH 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
	F——NH 0 == N-= 0 == N-= 0	N NH O II N N S N N N N S N N N N N N N N N N

10/079,452 20832Y

Case No.: Page No.:

19

or a pharmaceutically acceptable salt thereof.

Claim 42(withdrawn):

The compound according to Claim 1, wherein said compound is

or a pharmaceutically acceptable salt thereof.

Claim 43(previously presented):

A compound represented by

10/079,452 20832Y

Case No.: Page No.:

20

or a pharmaceutically acceptable salt thereof.

Claim 44(previously presented): The compound according to Claim 1, wherein said compound is

10/079,452 20832Y

Case No.: Page No.:

21

	HN N N
HN N NH ₂	
	O N N N N N N N N N N N N N N N N N N N

10/079,452 20832Y

Page No.:

22

or a pharmaceutically acceptable salt thereof.

Claim 45(previously presented): The compound according to Claim 1, wherein said compound is

Serial No.: Case No.: Page No.:

10/079,452 20832Y 23

		F N N N N N N N N N N N N N N N N N N N
F N N N N N N N N N N N N N N N N N N N		F N N F F
F N F	F F	I N N N N N N N N N N N N N N N N N N N
F N N N N N N N N N N N N N N N N N N N	T N N N N N N N N N N N N N N N N N N N	N= N= N= F
N N N N N N N N N N N N N N N N N N N	N H N H	

Serial No.: Case No.: Page No.:

10/079,452 20832Y 24

F N N N N N N N N N N N N N N N N N N N	H N N F	O HN N Br
HN-N-SI-	O HN N=	N HN N N
O HN N		
F F		
F N N N N N N N N N N N N N N N N N N N	H N N N N N N N N N N N N N N N N N N N	

10/079,452 20832Y 25

Page No.:

H N F F		
P F F		
I N N N N N N N N N N N N N N N N N N N	T N N N N N N N N N N N N N N N N N N N	T N N F
	F N N N N N N N N N N N N N N N N N N N	
O N H F		

or a pharmaceutically acceptable salt thereof.

Claim 46(previously presented): The compound according to Claim 1, wherein said compound is

10/079,452 20832Y

Case No.: Page No.:

26

$$S$$
 N
 N
 N
 N
 N

or a pharmaceutically acceptable salt thereof.

Claim 47(withdrawn):

The compound according to Claim 1, wherein said compound is

or a pharmaceutically acceptable salt thereof.

Claim 48(original): A pharmaceutical composition comprising an inert carrier and an effective amount of a compound according to claim 1.

Claim 49(previously presented): A pharmaceutical composition comprising an inert carrier and an amount of a compound according to claim 1 effective to treat pain.

Claim 50(previously presented): A pharmaceutical composition comprising an inert carrier and an amount of a compound according to claim 1 effective to treat migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke.

Claim 51(original): A method of treating pain comprising a step of administering to one in need of such treatment an effective amount of a compound according to claim 1.

10/079,452 20832Y

Case No.: Page No.:

27

Claim 52(original): A method of treating migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke comprising a step of administering to one in need of such treatment an effective amount of a compound according to claim 1.

Ş